Information Provided By:
Fly News Breaks for October 19, 2018
RMTI
Oct 19, 2018 | 07:06 EDT
IFS Securities analyst David Bouchey downgraded Rockwell Medical to Outperform with a $11 price target saying he remains bullish on the company, but said it is getting difficult to forecast events. Bouchey expects CMS to provide only partial clarity on reimbursement for IV versus dialysate Triferic, believes investors will need to wait until after FDA approval for CMS to either issue a new J code or not for IV Triferic and said there is uncertainty on the timing and size of revenue streams.
News For RMTI From the Last 2 Days
There are no results for your query RMTI